Key facts
- It has raised $40.2M; the latest was Grant ($6.5M) in Feb 2025.
- Notable investors include Novo Holdings, Innosuisse, CARB-X, AXA Investment Managers, Adjuvant Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for LimmaTech Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for LimmaTech Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LimmaTech Biologics
Operator of a clinical-stage biopharmaceutical firm focused on the prevention of life-threatening diseases. The company specializes in the research, development, and manufacture of bioconjugate vaccines using glycoengineering, protein glycosylation, and in vivo enzyme-based method that alleviates the issues associated with the chemical conjugation process and helps in the advancement of vaccines for multiple pathogens, enabling healthcare sectors to develop inoculation efficiently and reducing the time and cost.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2015
- Employees
- 53
- Website
- lmtbio.com/
- Ownership
- Privately Held (backing)
LimmaTech Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LimmaTech Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LimmaTech Biologics in its N-PORT filings yet. We sweep new filings monthly.